公开(公告)号：US20230088070A1

公开(公告)日：2023-03-23

申请号：US17728265

申请日：2022-04-25

Applicant: NOVARTIS AG

Inventor： Andreas BRUEDERLE ,  Anshu MARATHE ,  Jean REGARD ,  Mikael Lee RINNE ,  Haiying SUN ,  K. Gary J. VANASSE ,  Connie WONG

IPC: C07K16/24 ,  A61P35/04 ,  C07K16/28

Abstract: Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.

公开(公告)号：US20230057071A1

公开(公告)日：2023-02-23

申请号：US17786717

申请日：2020-12-03

Applicant: NOVARTIS AG

Inventor： K. Gary J. VANASSE ,  Haiying SUN ,  Mirek DOSTALEK ,  Mikael RINNE ,  Anshu MARATHE ,  Luigi MANENTI ,  Claire FABRE ,  Fariba KHANSHAN

IPC: C07K16/22 ,  C07K16/28 ,  C07K16/24 ,  A61K31/706 ,  A61P35/00

Abstract: Combination therapies comprising TIM-3 inhibitors and TGF-β inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.

公开(公告)号：US20200369762A1

公开(公告)日：2020-11-26

申请号：US16719154

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Andreas BRUEDERLE ,  Anshu MARATHE ,  Jean REGARD ,  Mikael RINNE ,  Haiying SUN ,  K. Gary J. VANASSE ,  Connie WONG

IPC: C07K16/24 ,  C07K16/28 ,  A61P35/04

Abstract: Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.